Competitive enzyme immunoassay for urinary vanillylmandelic acid

Area of Science:

• Biochemistry
• Analytical Chemistry
• Clinical Diagnostics

Background:

• Vanillylmandelic acid (VMA) is a key metabolite of catecholamines.
• Accurate measurement of urinary VMA is crucial for diagnosing certain medical conditions.
• Existing methods may have limitations in sensitivity, specificity, or ease of use.

Purpose of the Study:

• To develop and validate a novel enzyme immunoassay (EIA) for the direct measurement of urinary VMA.
• To assess the sensitivity, precision, and specificity of the developed EIA.
• To compare the performance of the EIA with a standard High-Performance Liquid Chromatography (HPLC) method.

Main Methods:

• Development of an enzyme immunoassay utilizing polyclonal antiserum and a VMA-acetylcholinesterase conjugate.
• Preparation of immunogens using two distinct strategies.
• Enantioselectivity demonstration and validation using D(-)-VMA as the standard.
• Assessment of Minimum Detection Concentration (MDC), precision (CV), cross-reactivity, repeatability, and recovery.
• Correlation analysis with HPLC for human urine samples.

Main Results:

• The EIA demonstrated high sensitivity with an MDC of 0.1 µmol/l.
• Excellent precision was achieved (CV < 7% in the 0.2–2.25 µmol/l range).
• Minimal cross-reactivity was observed with homovanillic acid (HVA) (0.8%) and other related metabolites (< 0.4%).
• High correlation (r² = 0.98) was found between the EIA and HPLC methods for both normal and pathological urine samples.

Conclusions:

• The developed enzyme immunoassay provides a sensitive, precise, and specific method for quantifying urinary VMA.
• The EIA method shows excellent agreement with HPLC, making it a viable alternative for clinical diagnostics.
• This assay facilitates direct measurement of urinary VMA, potentially simplifying diagnostic workflows.